linjc16/ctgov huggingface dataset:
Water and the Gastropressor Response - Tachyphylaxis

Study Overview
=================
Brief Summary
-----------------
We are studying the effects of oral water ingestion in patients with orthostatic hypotension. In this study, we are testing the null hypothesis that the blood pressure increase with oral water ingestion will not be diminished if a full prior water dose is given a few hours earlier.

Detailed Description
-----------------
We are studying the effects of oral water ingestion in patients with orthostatic hypotension. This has been termed the Gastropressor Response. In this study, we are testing the null hypothesis that the blood pressure increase with oral water ingestion will not be diminished if a full prior water dose is given a few hours earlier. In this 2 day study, subjects will be asked to drink with 1 oz or 16 oz of water in the morning followed a few hours later by 16 oz water while the blood pressure is monitored. On the 2nd day, the other dose of water will be given to start, with 16 oz again as the second dose.

Official Title
-----------------
Water and the Gastropressor Response - Tachyphylaxis (Specific Aim 1.2)

Conditions
-----------------
Orthostatic Hypotension

Intervention / Treatment
-----------------
* Other: water high dose
* Other: water tiny dose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: orthostatic hypotension (fall in BP>20/10 mmHg) pressor response to water in other studies Age 18-80 years Exclusion Criteria: pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>16 oz water in AM | Other: water high dose<br>* water 16 oz PO x 1<br>|
| Active Comparator: 2<br>water 1 oz in AM | Other: water tiny dose<br>* water 1 oz PO x 1<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood pressure |  | 2nd water intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| heart rate |  | 2nd intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
water, orthostatic hypotension, blood pressure
Weaning Outcome From Invasive Mechanical Ventilation

Study Overview
=================
Brief Summary
-----------------
The main purpose of the present study was to explore the weaning failure rate from invasive mechanical ventilation and to identify risk factors of weaning failure.

Official Title
-----------------
Weaning Outcome From Invasive Mechanical Ventilation: a Prospective, Observational Cohort Study

Conditions
-----------------
Patients Requiring Endotracheal Intubation and Invasive Mechanical Ventilation

Intervention / Treatment
-----------------
* Device: Invasive mechanical ventilation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Requiring endotracheal intubation and invasive mechanical ventilation Exclusion Criteria: Duration of invasive mechanical ventilation < 48 hours； Presence of tracheostomy； Presence of upper airway obstruction.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Invasive mechanical ventilation|Invasive ventilation was performed to all eligible patients. When patients met predefined criteria, spontaneous breathing trial was performed. Given spontaneous breathing trial passed, patients were extubated; on the contrary, patients would continue to receive invasive ventilation. If patients had respiratory failure after extubation, reintubation and invasive ventilation were necessary.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weaning failure rate |  | 3.5 years | 
| Spontaneous breathing trial failure rate |  | 3.5 years | 
| Extubation failure rate |  | 3.5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ICU mortality |  | 3.5 years | 
| Hospital mortality |  | 3.5 years | 
| ICU length of stay |  | 3.5 years | 
| Hospital length of stay |  | 3.5 years |
Ultrasound Guided Blocks of the Iliohypogastric and Ilioinguinal Nerves in Persistent Postherniorrhaphy Pain Patients

Study Overview
=================
Brief Summary
-----------------
In this controlled study the investigators will examine the analgesic and sensory effects of ultrasound-guided blocks of the iliohypogastric and ilioinguinal nerves with lidocaine in persistent postherniorrhaphy pain patients.

Official Title
-----------------
Ultrasound Guided Blocks of the Iliohypogastric and Ilioinguinal Nerves in Persistent Postherniorrhaphy Pain Patients

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: lidocaine
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients older than 18 years with severe postherniorrhaphy pain (numerical rating scale [NRS] > 6) for more than 6 month Exclusion Criteria: known amide local anesthetic drug allergy recurrent hernia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: lidocaine<br>lidocaine block | Drug: lidocaine<br> <br> |
| Placebo Comparator: Placebo<br> | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes (lidocaine vs. placebo) in pain perception, sensory mapping and QST compared to pre-block values. |  | 20 minutes after the block | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
persistent postherniorrhaphy pain
Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)

Study Overview
=================
Brief Summary
-----------------
This is a Phase II randomized, double-masked study comparing the safety and efficacy of ATG003 (mecamylamine HCl) 1.0% and 0.3% ophthalmic solutions to placebo in patients with neovascular (wet) age-related macular degeneration (NV-AMD).

Official Title
-----------------
A Phase II Randomized, Double-Masked, Study Comparing the Safety and Efficacy of ATG003 in Patients With Neovascular (Wet) Age-Related Macular Degeneration (NV-AMD)

Conditions
-----------------
Macular Degeneration

Intervention / Treatment
-----------------
* Drug: Mecamylamine
* Drug: Placebo


Participation Criteria
=================

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1% mecamylamine<br> | Drug: Mecamylamine<br> <br> |
| Active Comparator: 0.3% mecamylamine<br> | Drug: Mecamylamine<br> <br> |
| Placebo Comparator: Placebo<br> | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of Subjects Losing Fewer Than 15 ETDRS Letters of Visual Acuity at 48 Weeks Compared to Baseline. |  | Baseline to Week 48 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AMD, Wet AMD
Gene Expression Profiling in Human Gastric Intestinal Metaplasia Mucosa and Duodenal Mucosa

Study Overview
=================
Brief Summary
-----------------
To analyze the genome pattern in human gastric Intestinal Metaplasia Mucosa and duodenal Mucosa.

Official Title
-----------------
Gene Expression Profiling in Human Gastric Intestinal Metaplasia Mucosa and Duodenal Mucosa.

Conditions
-----------------
Gene Expression Profiling, Gastric Intestinal Metaplasia, Duodenum

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for gastroendoscopy examination Exclusion Criteria: Esophageal, gastric or duodenal cancer or other malignancy History of upper GI tract surgery Coagulopathy or bleeding disorders Allergy to fluorescein sodium

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gene Expression Profiling in Human Gastric Intestinal Metaplasia Mucosa and Duodenal Mucosa |  | 6 months |
Brain Functional Connectivity Changes Following Cognitive Rehabilitation in Multiple Sclerosis: an fMRI Study

Study Overview
=================
Brief Summary
-----------------
This trial seeks to investigate brain network changes following cognitive rehabilitation in MS patients. The investigators hypothesize that rehabilitation interventions improve connectivity in the brain.Novel Magnetic Resonance Imaging technique is performed to investigate changes in brain plasticity.

Conditions
-----------------
MS (Multiple Sclerosis)

Intervention / Treatment
-----------------
* Behavioral: Cog Rehab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Definitive MS diagnosis Right handedness EDSS 0-4 No relapse in past 6 weeks Willing to consent and participate in the study Exclusion Criteria: Pregnancy Left handedness Neurologic or psychiatric disorder other than MS

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 54 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Rehab first<br> | Behavioral: Cog Rehab<br>* Cognitive rehab for MS patients<br>|
| Experimental: Rehab Second<br> | Behavioral: Cog Rehab<br>* Cognitive rehab for MS patients<br>|
| No Intervention: Non Rehab<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| functional connectivity | Changes in correlation of brain activity in different regions of brain as assessed by Blood Oxygenation Level Dependent (BOLD) signal | 0, 2nd, 4th Month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Multiple Sclerosis, MRI Scans
Estimation of Gestational Age by TCD

Study Overview
=================
Brief Summary
-----------------
- Different parameters are used to estimate gestational age AC, HC , BPD and FL

Detailed Description
-----------------
-TCD is one of the parameters ,here we are testing its accuracy in calculating GA

Official Title
-----------------
Estimation of Gestational Age by Transcerebellar Diameter in Normal and Abnormal Pregnancy States

Conditions
-----------------
Gestational Age and Weight Conditions

Intervention / Treatment
-----------------
* Diagnostic Test: Ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant ladies with GA between 16 - 40 weeks Exclusion Criteria: pregnant ladies with GA less than 16 weeks

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 42 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control group<br>Pregnant ladies with no medical disorders from 16 weeks till term | Diagnostic Test: Ultrasonography<br>* Ultrasonography with biometry and TCD measurement<br>|
| case group<br>Pregnant ladies with medical disorders from 16 weeks till term | Diagnostic Test: Ultrasonography<br>* Ultrasonography with biometry and TCD measurement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of participants who will be exactly dated by TCD in comparison to LMP | The number of participants who will be exactly dated by TCD in comparison to LMP in weeks | within 4 months |
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects

Study Overview
=================
Brief Summary
-----------------
This trial is a Phase 2, randomized, controlled study to compare the degree of mucosal injury after the oral administration of an investigational product, PL2200, and a marketed 325 mg immediate-release aspirin product.

Detailed Description
-----------------
Each group will be treated with either an immediate-release aspirin tablet or PL2200 capsule at 325 mg per day for 6 weeks, and evaluated via an endoscope for any gastrointestinal injury that may have been caused by study medication.

Official Title
-----------------
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects

Conditions
-----------------
Gastroduodenal Ulceration

Intervention / Treatment
-----------------
* Drug: PL2200
* Drug: Aspirin tablets


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteers, ≥50 and ≤75 years of age. No endoscopically observed baseline gastrointestinal lesions. Exclusion Criteria: Baseline gastrointestinal lesions or abnormal screening/baseline laboratory parameters deemed clinically significant by the Investigator. Significant history of substance abuse or uncontrolled acute or chronic medical illness. Active H. pylori infection. Current use of low-dose aspirin for cardioprevention, or other ulcerogenic medications, gastroprotective, or anti-platelet agents. Hypersensitivity to aspirin or other NSAIDs.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PL2200<br>Investigational product, PL2200 | Drug: PL2200<br>* PL2200, containing 325 mg aspirin active ingredient<br>* Other names: PL-ASA;|
| Active Comparator: Aspirin tablets<br>Active comparator, 325 mg aspirin tablets | Drug: Aspirin tablets<br>* 325 mg aspirin tablets (USP)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Gastroduodenal Ulcers | Cumulative Incidence of Gastroduodenal Ulcers Greater than or equal to 3 mm in length with unequivocal depth | 42 Days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Subjects With Erosion and Ulcers | >5 erosions or ulcers 3 mm or greater in length with unequivocal depth, by endoscopy | 42 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Healthy volunteer, comparison of incidence of, treatment groups.
Control of Hypertension by Non-Pharmacologic Means

Study Overview
=================
Brief Summary
-----------------
To determine whether blood pressure could be controlled by nutritional-hygienic, non-pharmacologic means in hypertensives treated with drugs in the Hypertension Detection and Follow-up Trial (HDFP).

Detailed Description
-----------------
BACKGROUND: In the 1970s, many studies had been conducted to control blood pressure in individuals maintained at normotensive levels by the use of weight control and sodium restriction without the concomitant use of anti-hypertensives. The associations between weight, sodium and blood pressure had been well established, but data on the relationship of intervention to blood pressure control had been less so. DESIGN NARRATIVE: Patients were randomly assigned to one of three groups. The 95 patients in Group I were advised to control weight, reduce sodium intake, modify dietary and alcohol intake and were removed from pharmacologic treatment. The 44 patients in Group II were removed from pharmacologic treatment, with no other intervention. The 48 patients in Group III were continued on pharmacologic treatment, with no other intervention. The primary endpoint was the proportion in Groups I and II with diastolic blood pressure less than or equal to 90 mm Hg in the absence of antihypertensive drugs. Secondary endpoints were average diastolic and systolic pressures. The study completion date listed in this record was obtained from the CRISP legacy data.

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases, Hypertension, Vascular Diseases

Intervention / Treatment
-----------------
* Behavioral: diet, sodium-restricted
* Behavioral: diet, reducing
* Behavioral: alcohol restriction
* Drug: antihypertensive agents


Participation Criteria
=================
Eligibility Criteria
-----------------
Men and women with controlled hypertension.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: diet, sodium-restricted|nan|
|Behavioral: diet, reducing|nan|
|Behavioral: alcohol restriction|nan|
|Drug: antihypertensive agents|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Efficacy of Kyphoplasty With a New Intervertebral Expander

Study Overview
=================
Brief Summary
-----------------
Balloon kyphoplasty is a well-established treatment option to achieve pain relief and to correct kyphotic deformity caused by osteoporotic vertebral compression fracture. However, it has been demonstrated that reduction is partly lost as balloon is deflated in the vertebral body. An intravertebral expander was developed for better reduction and maintenance of vertebral body height while cement is injected. This study evaluates the efficacy of kyphoplasty with a new intravertebral expander with regard to correction of kyphosis angel and to restoration of vertebral body height.

Official Title
-----------------
Efficacy of Kyphoplasty With an Intravertebral Expander for Correction of Spine Deformity After Osteoporotic Vertebral Fracture

Conditions
-----------------
Vertebral Body Compression

Intervention / Treatment
-----------------
* Procedure: Kyphoplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Osteoporotic vertebral body fractures that were classified as A1 fractures according to Arbeitsgemeinschaft Osteosynthesis (AO) Classification Exclusion Criteria: More than 2 vertebral body fractures Fractures of vertebral body based on malignancy Previous spinal operation Spinal infection Spinal deformity (scoliosis)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Kyphoplasty<br>Patients underwent kyphoplasty with an intravertebral expander | Procedure: Kyphoplasty<br>* Fractured vertebral body was reduced with an intravertebral expander and was cement augmented thereafter<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Radiological evaluation | Kyphosis angle in degree and vertebral body height in cm are measured on lateral x-ray | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analogue Scale | Scores range from 0 (no pain) to 10 (worst possible pain) | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vertebral fracture, Kyphotic deformity, Kyphoplasty, Vertebroplasty